Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis

Yifei Chen; Tao Wang; Wei Wang; Jiahao Hu; Ruiting Li; Shaojun He; Jiong Yang

doi:10.18632/oncotarget.19244

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis

Yifei Chen, Tao Wang, Wei Wang, Jiahao Hu, Ruiting Li, Shaojun He and Jiong Yang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:62537-62544. https://doi.org/10.18632/oncotarget.19244

Metrics: PDF 1565 views | HTML 2689 views | ?

Abstract

Yifei Chen1,*, Tao Wang2,*, Wei Wang1, Jiahao Hu1, Ruiting Li1, Shaojun He1 and Jiong Yang1

1Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P. R. China

2Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Jiong Yang, email: [email protected]

Keywords: NSCLC, SIRT1, overall survival, prognosis, meta-analysis

Received: February 25, 2017 Accepted: June 04, 2017 Published: July 12, 2017

ABSTRACT

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The prognosis of NSCLC is extremely poor and it is urgently to find a new marker. Numerous studies have confirmed that silent mating type information regulation 2 homolog-1 (sirtuin1; SIRT1) is abnormally expressed in NSCLC. This meta-analysis was performed to investigate the prognostic and clinicopathological significance of SIRT1 in NSCLC. A total of seven eligible studies, including 6 on clinicopathological features, 7 on prognosis were identified from the databases. Pooled hazard ratios (HRs) or odds ratios (OR) and 95% confidence intervals (95% CIs) were calculated using random- or fixed-effects models. Results revealed that high expression of SIRT1 was associated with poor overall survival in NSCLC patients (HR=1.99, 95% CI: 1.33-2.98, P=0.0009). Moreover, SIRT1 were related to histological grade (OR= 2.00, 95% CI= 1.05–3.78, P= 0.02) of NSCLC patients. In conclusion, our present meta-analysis indicated that SIRT1 may serve as a promising marker for prognosis of patients with NSCLC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19244

Publication Alerts

Post-Publication Promotion

Publication Discount

Meta-Analysis:

Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis

Abstract